To restore T-cell activity and prevent cancer cells from evading the immune system, several immune checkpoint inhibitors, including Nivolumab, Pembrolizumab, Dostarlimab, and Durvalumab, have been investigated for their potential in treating CLL by targeting the PD-1/PD-L1 pathway [8]. This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.